Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma

References

• Thomä NH, Czyzewski BK, Alexeev AA, Mazin AV, Kowalczykowski SC, Pavletich NP. Structure of the SWI2/SNF2 chromatin-remodeling domain of eukaryotic Rad54. Nat Struct Mol Biol. 2005;12(4):350–356. doi:10.1038/nsmb919
   PubMed Web of Science ®Google Scholar
• Alexeev A, Mazin A, Kowalczykowski SC. Rad54 protein possesses chromatin-remodeling activity stimulated by the Rad51-ssDNA nucleoprotein filament. Nat Struct Biol. 2003;10(3):182–186. doi:10.1038/nsb901
   PubMedGoogle Scholar
• Van Komen S, Petukhova G, Sigurdsson S, Stratton S, Sung P. Superhelicity-driven homologous DNA pairing by yeast recombination factors Rad51 and Rad54. Mol Cell. 2000;6(3):563–572. doi:10.1016/s1097-2765(00)00055-1
   PubMed Web of Science ®Google Scholar
• Mazin AV, Alexeev AA, Kowalczykowski SC. A novel function of Rad54 protein. Stabilization of the Rad51 nucleoprotein filament. J Biol Chem. 2003;278(16):14029–14036. doi:10.1074/jbc.M212779200
   PubMed Web of Science ®Google Scholar
• Wright WD, Heyer WD. Rad54 functions as a heteroduplex DNA pump modulated by its DNA substrates and Rad51 during D loop formation. Mol Cell. 2014;53(3):420–432. doi:10.1016/j.molcel.2013.12.027
   PubMed Web of Science ®Google Scholar
• Tong Y, Merino D, Nimmervoll B, et al. Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus Carcinoma Oncogenes. Cancer Cell. 2015;27(5):712–727. doi:10.1016/j.ccell.2015.04.005
   PubMed Web of Science ®Google Scholar
• Wyman C, Kanaar R. DNA double-strand break repair: all’s well that ends well. Annu Rev Genet. 2006;40:363–383. doi:10.1146/annurev.genet.40.110405.090451
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou T, Chen H, Wen S, Dao P, Chen M. 54L promotes bladder cancer progression by regulating cell cycle and cell senescence. Med Oncol. 2022;39(12):185. doi:10.1007/s12032-022-01751-7
   PubMed Web of Science ®Google Scholar
• Li D, Frazier M, Evans DB, et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol. 2006;24(11):1720–1728. doi:10.1200/JCO.2005.04.4206
   PubMed Web of Science ®Google Scholar
• Mun JY, Baek SW, Park WY, et al. E2F1 Promotes Progression of Bladder Cancer by Modulating RAD54L Involved in Homologous Recombination Repair. Int J Mol Sci. 2020;21(23):9025. doi:10.3390/ijms21239025
   PubMed Web of Science ®Google Scholar
• Li Q, Xie W, Wang N, Li C, Wang M. CDC7-dependent transcriptional regulation of RAD54L is essential for tumorigenicity and radio-resistance of glioblastoma. Transl Oncol. 2018;11(2):300–306. doi:10.1016/j.tranon.2018.01.003
   PubMed Web of Science ®Google Scholar
• Nathansen J, Lukiyanchuk V, Hein L, et al. Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L. Oncogene. 2021;40(24):4214–4228. doi:10.1038/s41388-021-01842-1
   PubMed Web of Science ®Google Scholar
• Flaus A, Martin DMA, Barton GJ, Owen-Hughes T. Identification of multiple distinct Snf2 subfamilies with conserved structural motifs. Nucleic Acids Res. 2006;34(10):2887–2905. doi:10.1093/nar/gkl295
   PubMed Web of Science ®Google Scholar
• Selemenakis P, Sharma N, Uhrig ME, et al. RAD51AP1 and RAD54L Can Underpin Two Distinct RAD51-Dependent Routes of DNA Damage Repair via Homologous Recombination. Front Cell Dev Biol. 2022;10:866601. doi:10.3389/fcell.2022.866601
   PubMed Web of Science ®Google Scholar
• Talens F, Jalving M, Gietema JA, Van Vugt MA. Therapeutic targeting and patient selection for cancers with homologous recombination defects. Expert Opin Drug Discov. 2017;12(6):565–581. doi:10.1080/17460441.2017.1322061
   PubMed Web of Science ®Google Scholar
• Friedberg EC, McDaniel LD, Schultz RA. The role of endogenous and exogenous DNA damage and mutagenesis. Curr Opin Genet Dev. 2004;14(1):5–10. doi:10.1016/j.gde.2003.11.001
   PubMed Web of Science ®Google Scholar
• Hustedt N, Durocher D. The control of DNA repair by the cell cycle. Nat Cell Biol. 2016;19(1):1–9. doi:10.1038/ncb3452
   PubMed Web of Science ®Google Scholar
• Wright WD, Shah SS, Heyer WD. Homologous recombination and the repair of DNA double-strand breaks. J Biol Chem. 2018;293(27):10524–10535. doi:10.1074/jbc.TM118.000372
   PubMed Web of Science ®Google Scholar
• Provasek VE, Mitra J, Malojirao VH, Hegde ML, Double-Strand DNA. Breaks as Pathogenic Lesions in Neurological Disorders. Int J Mol Sci. 2022;23(9):4653. doi:10.3390/ijms23094653
   PubMed Web of Science ®Google Scholar
• Zheng S, Yao L, Li F, et al. Homologous recombination repair rathway and RAD54L in early-stage lung adenocarcinoma. PeerJ. 2021;9:e10680. doi:10.7717/peerj.10680
   PubMed Web of Science ®Google Scholar
• Bong IPN, Ng CC, Othman N, Esa E. Gene expression profiling and in vitro functional studies reveal RAD54L as a potential therapeutic target in multiple myeloma. Genes Genomics. 2022;44(8):957–966. doi:10.1007/s13258-022-01272-7
   PubMedGoogle Scholar
• Li C, Ding J, Mei J. Comprehensive Analysis of Epigenetic Associated Genes on Differential Gene Expression and Prognosis in Hepatocellular Carcinoma. J Environ Pathol Toxicol Oncol. 2022;41(1):27–43. doi:10.1615/JEnvironPatholToxicolOncol.2021039641
   PubMed Web of Science ®Google Scholar
• Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17(3):139–152. doi:10.1038/s41575-019-0229-4
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting Tumor Microenvironment for Cancer Therapy. Int J Mol Sci. 2019;20(4):840. doi:10.3390/ijms20040840
   PubMed Web of Science ®Google Scholar
• Belli C, Trapani D, Viale G, et al. Targeting the microenvironment in solid tumors. Cancer Treat Rev. 2018;65:22–32. doi:10.1016/j.ctrv.2018.02.004
   PubMed Web of Science ®Google Scholar
• Hernández-Camarero P, López-Ruiz E, Marchal JA, Perán M. Cancer: a mirrored room between tumor bulk and tumor microenvironment. J Exp Clin Cancer Res. 2021;40(1):217. doi:10.1186/s13046-021-02022-5
   PubMed Web of Science ®Google Scholar
• De Cicco P, Ercolano G, Ianaro A. The New Era of Cancer Immunotherapy: targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. Front Immunol. 2020;11:1680. doi:10.3389/fimmu.2020.01680
   PubMed Web of Science ®Google Scholar
• Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. doi:10.1186/s12943-021-01428-1
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhou J, Li L, et al. Pericytes in the tumor microenvironment. Cancer Lett. 2023;556:216074. doi:10.1016/j.canlet.2023.216074
   PubMed Web of Science ®Google Scholar
• Palmeri M, Mehnert J, Silk AW, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022;7(1):100336. doi:10.1016/j.esmoop.2021.100336
   PubMed Web of Science ®Google Scholar
• Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232–1243. doi:10.1093/annonc/mdz116
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi GPD, Li TMB. MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Cancers. 2021;13(3):558. doi:10.3390/cancers13030558
   PubMed Web of Science ®Google Scholar
• Li H, Zhuang H, Gu T, et al. RAD54L promotes progression of hepatocellular carcinoma via the homologous recombination repair pathway. Funct Integr Genomics. 2023;23(2):128. doi:10.1007/s10142-023-01060-w
   PubMed Web of Science ®Google Scholar